Sarepta Inks Manufacturing Deal For Gene Therapy Program
Zacks Investment Research | Jun 13, 2018 09:45PM ET
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced that it has entered into a long-term strategic manufacturing partnership with privately-held Brammer Bio for the manufacturing and commercial supply of its potential micro-dystrophin gene therapy and other neuromuscular pipeline products.
The partnership will help Sarepta to focus on process development by leveraging Brammer Bio’s world-class manufacturing capabilities for clinical and commercial supply of its micro-dystrophin Duchenne muscular dystrophy (“DMD”) gene therapy products. Sarepta will also access Brammer Bio’s manufacturing facilities for future gene therapy programs such as Limb girdle muscular dystrophy (“LGMD”).
Sarepta is planning to initiate clinical studies to evaluate gene therapies by mid-2018.
Brammer Bio is a biotech company, which provides services for development and early phase to commercial manufacturing services for cell and gene therapies.
So far this year, Sarepta’s shares have rallied 73.9% against a 6.5% decrease registered by the industry . The rally can be attributed to strong product sales and its key pipeline candidate’s progress.
Sarepta has only one product in its commercial portfolio, Exondys 51, which is available for the treatment of DMD in the United States. The drug has performed well in 2017, generating sales of more than $150 million in its first full year of commercialization. The sales are expected to double in 2018. The drug is under review in EU.
Moreover, Sarepta’s most advanced pipeline candidate, golodirsen, demonstrated encouraging results in a mid-stage clinical study evaluating it in DMD patients. The candidate has also shown better efficacy than Exondys 51. Sarepta is planning to file regulatory application seeking golodirsen’s approval in the United States by the end of this year.
Apart from golodirsen, there are several other DMD candidates in early to mid-stage studies.
We remind investors that Pfizer (NYSE:PFE) is also developing a gene therapy for the treatment of DMD. An early-stage study was initiated in April.
Sarepta Therapeutics, Inc. Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.